Many assays still fall short in the effort to detect infectious diseases more rapidly and at the point of care. The challenge is not a lack of innovation, but rather unseen gaps in reagent quality, specificity, and reproducibility. Imagine being able to detect low-abundance pathogens, avoid cross-reactivity, and ensure consistency across batches from early discovery through scale-up.

This webinar will explore the common but often overlooked hurdles in developing sensitive and specific point-of-care diagnostics for respiratory viruses, antimicrobial-resistant bacteria, and complex microbial environments. We will highlight how precision-engineered antigens, antibodies, and molecular tools can improve signal detection, reduce background noise, and accelerate development timelines.

Through published examples and overview of the GenScript’s portfolio of IVD solutions, which include custom monoclonal antibodies, recombinant antigens, CRISPR enzymes, and NGS-ready oligos, participants will see how high-quality reagents combined with biological insight can lead to meaningful diagnostic advances. Whether you are working on lateral flow assays, ELISAs, or molecular tests, you will gain strategies to bring greater precision to every stage of assay development.

Learning Objectives:

1. Identify the key technical and biological challenges in developing sensitive and specific point-of-care assays for infectious diseases.

2. Explore molecular and immunological tools that can accelerate assay development timelines without compromising accuracy.

3. Recognize the benefits of working with an ISO-certified CRO partner for faster IVD commercialization.